May 16, 2023 7:45am EDT Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
May 15, 2023 8:30am EDT Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 08, 2023 8:05am EDT Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
May 04, 2023 8:05am EDT Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
Apr 26, 2023 8:00am EDT Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
Mar 31, 2023 8:22am EDT Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity
Mar 23, 2023 5:15pm EDT Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
Mar 21, 2023 8:00am EDT Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders